Related Experiment Video
Updated: Aug 17, 2026

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
Published on: April 21, 2014
Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion
Houman Ashrafian1, Charles Redwood, Edward Blair
1Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK.
Insights
Genetic mutations causing hypertrophic cardiomyopathy (HCM) likely impair energy production, not contraction. This energy deficit may explain HCM
Area of Science:
- Cardiovascular Genetics
- Molecular Cardiology
- Metabolic Disorders
Background:
- Hypertrophic cardiomyopathy (HCM) is a genetic heart disease primarily linked to sarcomeric protein defects.
- Previous theories suggested impaired contraction triggers compensatory hypertrophy, but evidence is inconsistent.
- Sarcomeric dysfunction in HCM requires re-evaluation of its underlying mechanisms.
Purpose of the Study:
- To investigate the role of energy metabolism in the pathogenesis of sarcomeric hypertrophic cardiomyopathy (HCM).
- To propose a new model for HCM development based on impaired ATP utilization.
- To explore the implications of compromised energetics for HCM clinical presentation and treatment.
Main Methods:
- Analysis of mutant contractile protein function.
- Utilizing mouse models of HCM.
- Reviewing clinical studies on hypertrophic cardiomyopathy patients.
Main Results:
- Sarcomeric HCM mutations are associated with inefficient ATP utilization, suggesting an energy deficit.
- Mutations in metabolic genes also cause HCM-like phenotypes, supporting a role for energetics.
- Compromised cellular energetics align with clinical observations like delayed onset and asymmetrical hypertrophy.
Conclusions:
- Inefficient ATP utilization, or energy depletion, is a proposed central mechanism in sarcomeric HCM.
- This energetic hypothesis may explain key clinical features of HCM.
- Understanding HCM energetics could inform new therapeutic strategies for HCM and other cardiac hypertrophy conditions.
Abstract:
Genetic analysis of hypertrophic cardiomyopathy (HCM), a mendelian form of cardiac hypertrophy, indicates that the primary defect is in sarcomeric function. However, the initial proposal that depressed myocardial contraction leads to a 'compensatory' hypertrophy has proven inconsistent with laboratory and clinical evidence. Drawing on observations of mutant contractile protein function, together with mouse models and clinical studies, we propose that sarcomeric HCM mutations lead to inefficient ATP utilization. The suggestion that energy depletion underlies HCM is supported by the HCM-like phenotype found with mutations in a variety of metabolic genes. A central role for compromised energetics would also help explain the unresolved clinical observations of delayed onset and asymmetrical hypertrophy in HCM, and would have implications for therapy in HCM and, potentially, in more-common forms of cardiac hypertrophy and failure.
Related Concept Videos
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure II: Pathophysiology
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

